Medicine
Uptravi 200 mcg tablet
Uptravi 200 mcg tablet is a prescription medicine containing Selexipag for oral use, marketed by Actelion Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Storage conditions for UPTRAVI for injection: Store the original carton…
Key facts
- Active ingredient (INN)
- Selexipag
- Brand
- Uptravi
- Strength
- 200 mcg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 1 bottle
- Marketing authorisation holder
- Actelion Pharmaceuticals
- Manufacturer
- Actelion Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Storage conditions for UPTRAVI for injection: Store the original carton containing glass vial in a refrigerator at 2 °C to 8 °C (36 ºF to 46 ºF) until use in order to protect from light. Store at 20 °C to 25 °C (68 °F to 77 °F). Excursions are permitted between 15 °C and 30 °C (59 °F and 86 °F).
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B01AC27 Selexipag
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 21 December 2015
- Identifiers
- RxCUI 1729007, 1729013, 1729027 +7DailyMed set ID a7a23b87-f892-4e2c-8e2e-ebf841220f90NDC 66215-602Application NDA207947
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle in 1 carton / 60 tablet, coated in 1 bottle | 66215-602-06 | Actelion Pharmaceuticals | 21 December 2015 |
| 1 bottle in 1 carton / 140 tablet, coated in 1 bottle | 66215-602-14 | Actelion Pharmaceuticals | 21 December 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Selexipag 200 mcg tablet.
Other strengths and forms of Selexipag
Clinical summary
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I), among other approved uses. It is available as tablets, kits and powder for injection for oral and intravenous use. MedsAcross supplies Selexipag for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SelexipagFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- UPTRAVI prescribing information (Actelion Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Uptravi: European public assessment report (EPAR) · European Medicines Agency
Need Uptravi 200 mcg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.